Ocular Therapeutix (OCUL) Total Non-Current Liabilities (2013 - 2026)

Ocular Therapeutix has reported Total Non-Current Liabilities for 11 years, with the latest figure at $150.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 7.29% year-over-year to $150.0 million; the trailing twelve-month figure through Mar 2026 stood at $150.0 million (up 7.29% YoY), and the FY2025 full-year result was $139.8 million, down 1.83% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $150.0 million, up from $139.8 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $150.0 million in Q1 2026, with the low at $94.6 million in Q1 2022.
• Average Total Non-Current Liabilities over 5 years is $124.1 million, with a median of $130.9 million recorded in 2023.
• Year-over-year, Total Non-Current Liabilities soared 42.07% in 2023 and slipped 3.43% in 2024.
• Tracing OCUL's Total Non-Current Liabilities over 5 years: stood at $107.6 million in 2022, then rose by 21.74% to $130.9 million in 2023, then gained by 8.79% to $142.4 million in 2024, then dropped by 1.83% to $139.8 million in 2025, then climbed by 7.3% to $150.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $150.0 million (Q1 2026), $139.8 million (Q4 2025), and $137.7 million (Q3 2025), per Business Quant data.

Peer Comparison